{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:22Z","timestamp":1793371522227,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    This report describes the efficacy and safety of equecabtagene autoleucel (eque-cel) as sequential therapy in a multiple myeloma (MM) patient complicated with renal failure. The patient was a 50-year-old male diagnosed with MM (IgD-\n                    <jats:italic>\u03bb<\/jats:italic>\n                    subtype, Durie-Salmon stage IIIB, ISS stage III, R-ISS stage II, 1q21+) with severe renal insufficiency. After 4 cycles of daratumumab, bortezomib, and dexamethasone (DVD)\/daratumumab, bortezomib, pomalidomide, and dexamethasone (DVPD) induction therapy, the patient achieved hematologic complete remission (CR) and underwent autologous hematopoietic stem cell transplantation (ASCT) for consolidation. During subsequent daratumumab, ixazomib, pomalidomide, and dexamethasone (DIPD) maintenance therapy, intolerance due to recurrent infections and myelosuppression prompted a switch to eque-cel sequential therapy. During treatment, grade I cytokine release syndrome (CRS) was observed, with no severe immune effector cell\u2013related toxicities such as immune effector cell-associated neurotoxicity syndrome (ICANS), infection, or hemophagocytic syndrome; however, hematologic toxicities including grade 3 thrombocytopenia, grade 2 neutropenia, and grade 1 anemia occurred. Efficacy evaluation at day 28 post-Chimeric antigen receptor T(CAR-T) infusion demonstrated CR with minimal residual disease (MRD) negativity. At 21 months of follow-up, the patient has not received any additional MM maintenance therapy and continues to maintain CR with MRD negativity. This case suggests that renal failure is not an absolute contraindication for CAR-T cell therapy, and that CAR-T cell therapy may serve as an alternative to novel agent therapy in selected patients who are intolerant to long-term drug treatment, yielding favorable outcomes, although further validation in more cases and prospective studies is still required.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1911590","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:43:46Z","timestamp":1790138626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Yihao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, General Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1038\/bcj.2014.55","article-title":"Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis","volume":"4","author":"Lu","year":"2014","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e23057","DOI":"10.1002\/jcla.23057","article-title":"Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis","volume":"34","author":"Song","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3760\/cma.j.cn121090-20251130-00559","article-title":"[Guidelines for the diagnosis and management of first relapsed multiple myeloma in China (2026)]","volume":"47","year":"2026","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/s41409-020-0930-5","article-title":"Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma with renal impairment","volume":"55","author":"Li","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1911590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:43:50Z","timestamp":1790138630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1911590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1911590"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1911590","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1911590"}}